HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).

Abstract
Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.
AuthorsNobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima
JournalInternational journal of cancer (Int J Cancer) Vol. 122 Issue 2 Pg. 461-7 (Jan 15 2008) ISSN: 1097-0215 [Electronic] United States
PMID17935130 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Retracted Publication)
CopyrightCopyright 2007 Wiley-Liss, Inc.
Chemical References
  • Macrophage-Activating Factors
  • Vitamin D-Binding Protein
  • vitamin D-binding protein-macrophage activating factor
  • alpha-N-Acetylgalactosaminidase
  • Tetradecanoylphorbol Acetate
Topics
  • Adult
  • Aged
  • Breast Neoplasms (diagnosis, metabolism, therapy)
  • Female
  • Glycosylation
  • Humans
  • Immunotherapy (methods)
  • Macrophage Activation
  • Macrophage-Activating Factors (metabolism)
  • Macrophages (metabolism)
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis
  • Tetradecanoylphorbol Acetate (pharmacology)
  • Vitamin D-Binding Protein (chemistry, metabolism)
  • alpha-N-Acetylgalactosaminidase (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: